SC-202

SC-202 is a preclinical nanobody-drug conjugate (NDC) being developed by Tianjin ConjuStar Biologics for the treatment of oncology. As an NDC, it utilizes a nanobody—a small, single-domain antibody fragment—as a targeting moiety linked to a cytotoxic payload. This modality is designed to address the limitations of traditional antibody-drug conjugates (ADCs), such as low target binding capacity and poor tumor penetration, by leveraging the smaller size and high stability of nanobodies to selectively deliver cell-killing agents to tumor cells. The specific molecular target and payload for SC-202 have not been publicly disclosed.